|
|
- 2017
非抗体结合蛋白－抗体组合的GPC3双夹心化学发光法在临床的初步应用
|
Abstract:
摘要 目的: 探讨非抗体结合蛋白－抗体双夹心化学发光免疫诊断试剂检测磷脂酰肌醇蛋白聚糖-3(GPC3)在肝细胞癌(HCC)血清学的临床诊断价值和鉴别诊断价值.方法: 应用本课题前期研制的非抗体结合蛋白－抗体GPC3夹心化学发光法诊断试剂检测HCC、肝内胆管癌、胃癌、肺癌、乳腺癌、正常人群等患者血清GPC3水平,同时用GPC3免疫组织化学(IHC)检测上述疾病患者的肿瘤组织,同时分析甲胎蛋白(AFP)和本实验方法对HCC的诊断效能,进一步分析GPC3表达于不同细胞结构部位与血清水平关系.结果:非抗体结合蛋白－抗体GPC3双夹心化学发光试剂盒检测HCC组GPC3血清水平明显高于其他组(>21倍,P值均小于0.01),与GPC3 IHC结果相一致.联合GPC3和AFP的曲线下面积(AUC)为0.922,明显高于单一标志物(GPC3和AFP的AUC分别为0.899和0.821,P值均小于0.05)的诊断价值.GPC3主要表达于胞膜和混合表达(胞膜和胞质),且所有胞膜和混合表达阳性患者血清样本的GPC3均高水平表达.结论:非抗体结合蛋白－抗体GPC3双夹心化学发光试剂盒具有良好的诊断特异性及准确性,有可能用于HCC的鉴别诊断,且对分析GPC3胞膜型HCC的诊断、疗效评价及预后提供更多诊断价值信息.
| [1] | NING S, BIN C, NA H, et al. Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients[J]. Mol Biol Rep, 2012, 39(1): 351-357. |
| [2] | CASTILLO L F, TASCON R, LAGO H M, et al. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells[J]. Oncotarget, 2016, 7(37): 60133-60154. |
| [3] | Lü G S, CHEN L, WANG H Y. Research progress and prospect of liver cancer in China[J]. Chinese Bulletin of Life Sciences, 2015,27(3):237-248. |
| [4] | 杨晓燕, 向 琼, 殷 杰, 等. miR-503下调Bcl-2增强BEL-7402/5-FU细胞对5-氟尿嘧啶的敏感性[J]. 暨南大学学报(自然科学与医学版), 2017,38(1): 25-29. |
| [5] | DUFOUR J F, GRETEN T F, RAYMOND E, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. Eur J Cancer, 2012, 48(5): 599-641. |
| [6] | 丛文铭, 步 宏, 陈 杰, 等. 原发性肝癌规范化病理诊断指南(2015版)[J]. 临床与实验病理学杂志, 2015,31(3): 241-246. |
| [7] | ZHANG Q, XIAO Q, LIN Z, et al. Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma[J]. Clin Biochem, 2010, 43(12): 1003-1008. |
| [8] | YU J P, XU X G, MA R J, et al. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma[J]. J Clin Lab Anal, 2015, 29(2): 85-93. |
| [9] | YU X, LI Y, CHEN S W, et al. Differential expression of glypican-3 (GPC3) in lung squamous cell carcinoma and lung adenocarcinoma and its clinical significance[J]. Genet Mol Res, 2015, 14(3): 10185-10192. |
| [10] | HIPPO Y, WATANABE K, WATANABE A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma[J]. Cancer Res, 2004, 64(7): 2418-2423. |
| [11] | LI B, LIU H, SHANG H W, et al. Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients[J]. Afr Health Sci, 2013, 13(3): 703-709. |
| [12] | YAN B, WEI J J, QIAN Y M, et al. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma[J]. Ann Diagn Pathol, 2011, 15(3): 162-169. |
| [13] | NAKAMOTO Y, GUIDOTTI L G, KUHLEN C V, et al. Immune pathogenesis of hepatocellular carcinoma[J]. J Exp Med, 1998, 188(2): 341-350. |
| [14] | TOYODA H, KUMADA T, OSAKI Y, et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers[J]. Clin Gastroenterol Hepatol, 2006, 4(12): 1528-1536. |
| [15] | CARR B I, KANKE F, WISE M, et al. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States[J]. Dig Dis Sci, 2007, 52(3): 776-782. |
| [16] | BAYATI N, SILVERMAN A L, GORDON S C. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C[J]. Am J Gastroenterol, 1998, 93(12): 2452-2456. |
| [17] | QIN S K. Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)[J]. Chin Clin Oncol, 2012,1(1):10-42. |
| [18] | 王莉琳, 张永宏, 陈新月. 2010年美国肝病年会(AASLD)肝细胞癌诊疗指南[J]. 北京医学, 2011,33(3): 236-251. |
| [19] | WANG L L,ZHANG Y H, CHEN X Y.AASLD practice guidelines for hepatocellular carcinoma in 2010 [J]. Beijing Medical Journal, 2011,33(3):236-251. |
| [20] | CONG W M, BU H,CHEN J, et al. Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China (2015 update)[J]. Chin J Clin Exp Pathol, 2015,31(3):241-246. |
| [21] | LUO J, YANG K, WEN Y G. Nested polymerase chain reaction technique for the detection of Gpc3 and Afp mRNA in liver cancer micrometastases.[J]. Genetics and Molecular Research,2017, 16(1): gmr16018947 |
| [22] | 吕桂帅, 陈 磊, 王红阳. 我国肝癌研究的现状与前景[J]. 生命科学, 2015,27(3): 237-248. |
| [23] | YANG X Y, XIANG Q, YIN J, et al. miRNA-195 sensitizes BEL-7402/5-FU cells to 5-fluorouracil via downpregulating Bcl-2 expression[J]. Journal of Jinan University (Natural Science &Medicine Edition),2017,38(1): 25-29. |
| [24] | HAN S, MA X, ZHAO Y, et al. Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer[J]. Oncotarget, 2016, 7(28): 44406-44416. |
| [25] | 中国抗癌协会肝癌专业委员会,中国抗癌协会临床肿瘤学协作专业委员会,中华医学会肝病学会,等. 原发性肝癌规范化病理诊断方案专家共识[J]. 临床与实验病理学杂志, 2010,26(06): 645-647. |
| [26] | CHINESE SOCIETY OF LIVER CANCER,CHINESE ANTI-CANCER ASSOCIATION, CHINESE SOCIETY OF CLINICAL ONCOLOGY, et al. Expert consensus on the scheme of pathological diagnosis of primary liver cancer[J]. Chin J Clin Exp Pathol,2010,26(6): 645-647. |
